Clark Hill’s Capital Markets team, led by Jim Groth and Jeny Zarmon, served as issuer’s counsel to HCW Biologics Inc. (Nasdaq: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, in its secured debt financing of up to $10 million.
The financing provided $3 million at closing and access to an additional $7 million, subject to certain conditions, to support the company’s clinical development programs and general corporate purposes.
Additional details regarding the transaction were announced in the company’s press release.
